September 07, 2026 08:09 pm (IST)

Make this your homepage

All Finance

‘No one can dictate what Bengalis eat’: BJP’s blunt message amid Bageshwar Baba’s Durga Puja food row | Delhi hostel collapse: Owner detained after seven die in Satya Niketan tragedy | No Muslims, Aadhaar card and tilak mandatory: VHP lays down rules for Garba, Dandiya in Maharashtra | 'No non-veg near Durga Puja pandals': Bageshwar Baba's big Bengal appeal sparks controversy | 'Law will take its action': Vijay's zero tolerance on insulting women weeks after Udhayanidhi's arrest | Delhi Metro's big warning to content creators: Don't try this viral stunt or face action | Hindutva influencer Swatantra Bhardwaj detained after viral assault clip; Chirag Paswan’s party files complaint for ‘falsely’ naming him | Bengaluru horror: Woman stripped, assaulted and filmed over unpaid loan interest; 4 arrested | West Bengal CM's big warning: Teacher suspended over tilak row, govt employee punished for PM Modi post | Tragedy on Kerala Highway: 8 Tamil Nadu students killed after car crashes into parked lorry

Aurobindo Pharma receives USFDA approval for drug related to moderate dementia

India Blooms News Service | | Mar 29, 2016, at 08:16 pm

Hyderabad/Mumbai, Mar 29 (IBNS) Aurobindo Pharma Limited, which manufactures generic pharmaceuticals and active pharmaceutical ingredients, announced on Tuesday that the company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg.

This product is expected to be launched in the first quarter of fiscal year 2016-17.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exelon Capsules, 1.5 mg, 3 mg, 4.5 mg and 6 mg, of Novartis Pharmaceuticals Corporation, said the company.

Naproxen Sodium Tablets is used in the treatment of mild moderate dementia of the Alzheimer's and Parkinson's disease.

The approved product has an estimated market size of US$ 26.7 million for the twelve months ending January 2016 according to IMS.

This is the 67th ANDA (including 14 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing oral non-antibiotic products.

Aurobindo now has a total of 246 ANDA approvals (211 Final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.

#Aurobindo Pharma receives USFDA # US Food & Drug Administration

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.

India
International

Related Images

In Images: Amit Shah performs 'Bhoomi Pujan' of Amul's curd manufacturing plant in Kolkata Jul 19, 2026, at 10:57 pm

Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:41 pm

Veedol signs former Indian skipper Sourav Ganguly as brand ambassador Jun 29, 2024, at 06:38 am